z-logo
Premium
Pulmonary hypertension in chronic obstructive pulmonary disease
Author(s) -
Gredic Marija,
Blanco Isabel,
Kovacs Gabor,
Helyes Zsuzsanna,
Ferdinandy Péter,
Olschewski Horst,
Barberà Joan Albert,
Weissmann Norbert
Publication year - 2021
Publication title -
british journal of pharmacology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.14979
Subject(s) - copd , medicine , intensive care medicine , pulmonary hypertension , pathophysiology , pulmonary disease , disease , bioinformatics , cardiology , biology
Even mild pulmonary hypertension (PH) is associated with increased mortality and morbidity in patients with chronic obstructive pulmonary disease (COPD). However, the underlying mechanisms remain elusive; therefore, specific and efficient treatment options are not available. Therapeutic approaches tested in the clinical setting, including long-term oxygen administration and systemic vasodilators, gave disappointing results and might be only beneficial for specific subgroups of patients. Preclinical studies identified several therapeutic approaches for the treatment of PH in COPD. Further research should provide deeper insight into the complex pathophysiological mechanisms driving vascular alterations in COPD, especially as such vascular (molecular) alterations have been previously suggested to affect COPD development. This review summarizes the current understanding of the pathophysiology of PH in COPD and gives an overview of the available treatment options and recent advances in preclinical studies. LINKED ARTICLES: This article is part of a themed issue on Risk factors, comorbidities, and comedications in cardioprotection. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.1/issuetoc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here